Tests SNC109 cell therapy in adults with recurrent glioblastoma brain tumors
Tests SNC109 in adults whose glioblastoma brain tumor has returned.
Plain-language title generated from the registry record
Registry title: The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose glioblastoma, a type of brain tumour, has come back. It tests the safety of SNC109 CAR-T cell therapy.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Recurrent glioblastoma (including astrocytoma WHO Grade 4), confirmed by tissue or molecular tests. Karnofsky score of 50 or more. Expected survival of 12 weeks or more.
- Earlier treatment
- No live or attenuated vaccine, and no surgery unrelated to glioblastoma, within 4 weeks before lymphocyte apheresis. No long-term immunosuppressant drugs or large steroid doses.
- Biomarker or test result
- Women who can have children need a negative blood pregnancy test.
Main reasons for not taking part
- Known allergy to the study drugs or drugs that may be used in the study
- Severe heart, lung, liver or other vital organ disease
- Poorly controlled high blood pressure, or hypertensive crisis or encephalopathy
- Other severe central nervous system disease, or another aggressive cancer
- Infection or unexplained fever at lymphocyte apheresis or cell infusion
Read by machine on 9 November 2026.
Where in China
- Chinese PLA General HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Simnova Biotechnology Co.,Ltd.
- Trial code
- NCT06616727
- Record updated
- 27 September 2024
- Original description
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBMRead full original descriptionShow less
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SNC109 in Patients With Recurrent Glioblastoma
A phase I study to evaluate the safety, tolerance and pharmacokinetics of SNC109 in patients with rGBM
Inclusion: Age ≥18，both sexes; Diagnosed with a history of glioblastoma, and the recurrent glioblastoma has confirmed by histological/molecular pathology (including astrocytoma World Health Organization (WHO) Grade 4); Karnofsky (KPS) ≥50; The estimated survival time is ≥12 weeks; Blood pregnancy tests for women of childbearing age are negative; The patient himself/herself, and/or his/her legal guardian, agree to participate in the trial and sign the informed consent form.
Exclusion: Severe concurrent diseases in the heart, lungs, liver, or other vital organs; Long-term use of immunosuppressant drugs, or large doses of steroids; Known allergies to study drugs or drugs that may be used in the study; Hypertension is poorly controlled or accompanied by hypertensive crisis or hypertensive encephalopathy; In addition to the glioblastoma, with other severe central nervous system diseases or complications or aggressive malignancies; Received live or attenuated vaccine or other surgery had no related to GBM within 4 weeks prior to Lymphocytes apheresis; Lymphocytes apheresis or cell infusion combined with infection or unexplained fever.